No one doubts that good nutrition is an important component of neonatal intensive care, nor that this can only be accomplished by the use of intravenous fat. With regard to the effects of nutrition on bronchopulmonary dysplasia, however, we are facing a dilemma. On the one hand there is the suggestion that inadequate nutrition increases the severity of bronchopulmonary dysplasia and on the other that the use of intravenous fat predisposes to it.
Very immature infants are born with extremely limited endogenous energy reserves and there is a pressing need to supplement these as soon as possible after birth. It can be calculated that the average 1000 g infant has enough stored energy to survive for about five days.1 The addition of a 10% dextrose infusion lengthens this theoretical survival time only to about 10 days, indicating that even with this external energy source endogenous reserves would soon be eroded to serve the needs of essential basal metabolism.
In addition to securing survival, modern neonatal medicine has as its aim the maximisation of developmental potential. Recent evidence shows that this too is significantly related to the quality of early nutrition. 2 There are therefore two good reasons to explore ways of implementing a nutritional regimen which minimises dependence on endogenous energy stores and, as soon as possible, begins to meet the requirements of the nervous system for the necessary substrates for growth.
The provision of complex nutrients to sick preterm infants who are struggling to adapt to extrauterine life carries, in common with almost all medical interventions, the possibility of doing more harm than good and must be carefully evaluated so that decisions about its use are appropriately informed. Published work about the early provision of parenteral nutrition to such infants3-6 certainly raises some concerns about safety, particularly of intravenous lipids, but is insufficient to inform clinical decision making. There is currently sufficient professional equipoise about the value of the early introduction of lipids into parenteral nutrition regimens to justify randomised comparative studies of different regimens.
Subjects and methods Preterm infants admitted to the Regional Neonatal Intensive Care Unit at St James's University Hospital, Leeds between January 1990 and November 1991 were considered for this trial.
Infants were allocated to one of two groups when they were between 12 and 24 hours of age. Allocation was random but included stratification according to gestation and the severity of lung disease, as determined by the pressure/shunt product at 12 hours of age. The pressure/shunt product is a validated index of the severity of respiratory distress syndrome7 which takes into account the inspired oxygen, the mean airway pressure, and the arterial oxygen tension.
SUBJECTS
Infants were entered into the study if their birth weight was equal to or less than 1750 g, if they were still requiring intermittent positive pressure ventilation (IPPV) at 12 hours of age, and had radiographic features of respiratory distress syndrome. Infants with severe congenital abnormalities or pulmonary hypoplasia were excluded from the study.
A total of 129 infants were recruited into the trial. Those infants randomised into the early group received parenteral nutrition within the first 36 hours; those in the late group received parenteral nutrition on the sixth complete day.
METHODS
In the two groups parenteral nutrition followed our standard regimen. Intralipid 20% (KabiVitrum) and either Vamin 9 glucose or Vamin Infant (KabiVitrum) were started at a dose of 0-5 g/kg/day and increased daily by this amount to a maximum of [3] [4] [5] g/kg/day. Lipid infusions were continuous over 24 hours. The fluid regimen was the same for the early and late groups; infants were started on 75 ml/kg/day of 10% dextrose solution and this was increased daily in increments to 165-180 ml/kg/day. Table 2 gives the nutritional intake received by the two groups during the first seven complete days of life. Most (116 (90%)) of the infants received parenteral nutrition only. A few (13 (10%)) were started on enteral feeds within the first seven days and these infants are included in the table only while receiving full parenteral nutrition. Table 3 compares the two groups with respect to the incidence and severity of chronic lung disease as shown by the duration of assisted ventilation and oxygen treatment. There was no significant difference between the two groups for any of these indices.
Forty (31%) infants developed chronic lung disease defined as oxygen dependency at 28 days of age. Twenty of these were in the early parenteral nutrition group and 20 in the late parenteral nutrition group. Table 3 also compares the two groups for age at discharge, average weight gain per day during the stay in hospital, and average weight gained by 2 weeks of age. There was no significant difference for any of these measures.
Data were also collected on the incidence of patent ductus arteriosus, intraventricular haemorrhage, and clinically important jaundice requiring treatment; there was no significant difference between the groups for these complications. Table 4 gives the plasma triglyceride concentrations in the two groups or infants.
Discussion
The components of parenteral nutrition that has given rise to most concern in neonatology are lipids, which are essential if the regimen is to contain sufficient energy to achieve the outlined objectives.
The use of intravenous lipids in preterm infants has been reported to be associated with a short term deterioration in pulmonary function, increased pulmonary vascular tone, and the deposition of lipid particles in alveolar macrophages and capillaries.4 5 89 All these effects might be expected to increase ventilatory requirements and so increase the incidence and severity of chronic lung disease.
Early or late parenteral nutrition for the sick preterm infant?
None of this work helps to determine the influence of the early introduction of parenteral lipids on any measure of medium or long term outcome. Two research studies, however, have suggested potentially serious medium term clinical complications of using intravenous lipids early in the course of neonatal intensive care.3 4 The first, a small randomised trial from Chicago4 allocated 42 infants to receive intravenous lipids either before or after 5 days of age and showed a significant increase in the incidence and severity of chronic lung disease in those infants given lipids earlier. We struggle to relate the findings of that study to our own practice as the duration of assisted ventilation and oxygen treatment in the Chicago cohort was so much greater than in our own group of infants of similar gestation and weight.
The second study, a large retrospective analysis performed in Liverpool,3 showed a statistically significant association between the earlier introduction of intravenous lipids and an increased incidence and severity of chronic lung disease, using the powerful tool of logistic regression. This finding certainly indicates the need for a prospective randomised control trial. One other small randomised trial of early versus late lipids did not show an adverse effect of early lipids on the development of chronic lung disease.'0 Our study did not show any detrimental effect on the course of neonatal lung disease of beginning a lipid-containing parenteral nutrition regimen within the first 36 hours of life as opposed to on the sixth day of life. This is despite the fact that the study had a 90% power to show a three day difference in the duration of IPPV, or a one week difference in the duration of oxygen treatment at the 5% level of significance. We chose these magnitudes of difference as being clinically significant. A larger trial would be needed to have a reasonable chance of detecting smaller differences.
In addition to looking for detrimental effects, it is also important to define and quantify the potential benefits of early and effective nutrition. Evidence is becoming available about the importance of early nutrition on long term growth and development. Lucas and coworkers have published several papers suggesting that the quality of nutrition over a brief, but perhaps critical, postnatal period has developmental consequences that persist into infancy.2
We did not show any significant benefit from early parenteral nutrition in terms of weight gain, though the trend at 2 weeks of age was in favour of the early nutrition group. We were not surprised by this as the difference in the intake of nutrients was relatively small and short lived. This does not, however, preclude the possibility of significant benefit if the extra nutrients were utilised preferentially by the central nervous system, as is usual under conditions of starvation at this stage of development.
